Drug Delivery in Central Nervous System Disorders
Technologies, Companies and Markets

By

Prof. K. K. Jain
MD, FRACS, FFPM
Jain PharmaBiotech
Basel, Switzerland

September 2016

A Jain PharmaBiotech Report
AUTHOR'S BIOGRAPHY

Professor K. K. Jain is a neurologist/neurosurgeon by training with specialist's qualifications. His personal experience includes some of the technologies mentioned in this report. He received graduate training in both Europe and USA, and has held academic positions in several countries. He is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK and has been working in the biotechnology/biopharmaceuticals industry for several years. Currently he is a consultant at Jain PharmaBiotech. Prof. Jain’s 460 publications include 26 books (5 as editor + 21 as author) and 50 special reports, which have covered important areas in biotechnology, neurology, and pharmaceuticals.


ABOUT THIS REPORT

The original report on Drug Delivery in CNS Diseases by the author was published by Decision Resources Inc in 2000 as an enlargement of the chapter on this topic in his report on Drug Delivery Technologies (1998), which was also published by Decision Resources. The second edition was rewritten and published at Jain PharmaBiotech in 2004 and is being constantly rewritten since then.

Copyright © 2016 by

Jain PharmaBiotech
Bläsiring 7
CH-4057 Basel
Switzerland

Tel & Fax: +4161-6924461
Email: info@pharmabiotech.ch
Web site: http://pharmabiotech.ch/

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise without the prior written permission of the Publisher. This report may not be lent, resold or otherwise traded in any manner without the consent of the Publisher. While all reasonable steps have been taken to ensure the accuracy of the information presented, the Publisher cannot accept responsibility for inadvertent errors or omissions.
# Table of Contents

0. Executive Summary .................................................................................................................. 14

1. Basics of Drug Delivery to the Central Nervous System .................................................. 16
   Introduction ............................................................................................................................... 16
   Historical evolution of drug delivery for CNS disorders ....................................................... 16
   Neuroanatomical and neurophysiological basis of drug delivery ........................................ 17
      The cerebrospinal fluid ........................................................................................................ 17
      The lymphatic drainage system of the brain ....................................................................... 18
      The extracellular space in the brain .................................................................................. 18
      Neurotransmitters .............................................................................................................. 19
      Extracellular vesicles as drug delivery vehicles ................................................................ 20
   Neuropharmacology relevant to drug delivery ....................................................................... 20
      Introduction to neuropharmacology .................................................................................. 20
      Pharmacokinetics ............................................................................................................... 21
      Absorption and distribution of drugs ................................................................................. 21
      Drug metabolism and elimination ..................................................................................... 21
      Pharmacodynamics ............................................................................................................ 21
      Receptors ............................................................................................................................ 21
      Sites of drug action in the CNS .......................................................................................... 22
         Receptors coupled to guanine nucleotide binding proteins .............................................. 22
         Acetylcholine receptor channels .................................................................................... 22
         Dopamine receptors ....................................................................................................... 23
         GABA receptor channels .............................................................................................. 23
         Glutamate receptor channels ....................................................................................... 23
         Non-competitive NMDA antagonists .............................................................................. 24
         Serotonin receptors ......................................................................................................... 24
      G-protein coupled receptors .............................................................................................. 24
      In vivo study of drug action in the CNS in human patients .................................................. 25
      Electroencephalography ..................................................................................................... 25
      Brain imaging ..................................................................................................................... 25
      Chronopharmacology as applied to the CNS .................................................................... 26
      Role of drug delivery in personalized therapy of CNS disorders ........................................ 27

2. Blood Brain Barrier ................................................................................................................. 28
   Introduction ............................................................................................................................... 28
   Features of the blood-brain barrier relevant to CNS drug delivery ...................................... 28
      The neurovascular unit ....................................................................................................... 28
      Functions of the BBB .......................................................................................................... 29
         BBB as an anatomical as well as physiological barrier .................................................... 29
         BBB as a biochemical barrier .......................................................................................... 30
      Role of shear stress on development of BBB .................................................................... 30
      Genomics of BBB ................................................................................................................ 30
      Proteomics of BBB ............................................................................................................. 30
      Other neural barriers ........................................................................................................ 31
         Blood-cerebrospinal fluid barrier .................................................................................... 31
         Blood nerve barrier ......................................................................................................... 32
         Blood-retinal barrier ......................................................................................................... 33
         Blood-labyrinth barrier .................................................................................................... 33
   Passage of substances across the blood-brain barrier ........................................................... 33
      Transporters localized in the BBB ....................................................................................... 34
         Glucose transporter ........................................................................................................... 34
         Amino acid transporters ................................................................................................. 35
         Ionic transporter ............................................................................................................. 35
         Efflux transport systems ............................................................................................... 36
      BBB-specific enzymes ......................................................................................................... 36
      Receptor-mediated transcytosis ......................................................................................... 37
      Lyosphosphatidic acid-mediated increase in BBB permeability ....................................... 37
      Pseudo transport system ................................................................................................... 38
      Transferrin receptor ........................................................................................................... 38
      Molecular biology of the BBB ........................................................................................... 39
      Transport of peptides and proteins across the BBB ........................................................... 39
         Passage of leptin across the BBB ..................................................................................... 39
         Passage of cytokines across the BBB .............................................................................. 39
         Passage of hormones across the BBB ............................................................................... 40
         Passage of enzymes across the BBB ............................................................................... 40
      Passage of omega-3 fatty acids across the BBB ................................................................. 41
      Drugs that cross the BBB by binding to plasma proteins .................................................. 41
3. Methods of Drug Delivery to the CNS

Introduction .................................................................................................................. 58

Routes of drug delivery to the brain .......................................................................... 59
Drug delivery to the brain via nasal route .................................................................. 59
Devices for nasal administration of drugs for CNS .................................................... 60
Nasal mucosal patch to facilitate drug delivery across the BBB .............................. 61
Passage of viruses to the brain via the nasal route ..................................................... 61
Potential and limitations of nasal drug delivery to the brain .................................... 61
Drugs that can be delivered to the brain via the nasal route ...................................... 62
Erythropoietin ............................................................................................................ 62
Esketamine ................................................................................................................. 62
Hypocretin .................................................................................................................... 62
IFN beta-1b .................................................................................................................. 62
Lysosomal enzymes ................................................................................................... 63
Midazolam .................................................................................................................... 63
Neurotrophic factors .................................................................................................. 63
Thyrotropin-releasing hormone .................................................................................. 64
Neuroprotective drugs for stroke .............................................................................. 64
Transdermal drug delivery for neurological disorders ............................................. 65
Drug delivery to the brain via inner ear ..................................................................... 65
Drug delivery for disorders of the spinal cord ......................................................... 65
Intrathecal drug delivery ............................................................................................. 65
Anatomical & physiological aspects of intrathecal drug delivery ............................ 66
Advantages of intrathecal drug delivery ................................................................. 66
Drugs that can be delivered by intrathecal route ...................................................... 67
Pharmacokinetics of intrathecal drug delivery ....................................................... 68
Retrograde delivery to the brain via the epidural venous system ............................. 70
Devices for drug delivery to the CNS ....................................................................... 70
Catheters for drug delivery to the CNS .................................................................... 70
Reservoirs and pumps for drug delivery to the CNS .............................................. 71
Invasive neurosurgical approaches .......................................................................... 71
Intraarterial drug delivery to the brain ...................................................................... 71
Direct injection into the CNS substance or CNS lesions ........................................ 72
Targeted delivery of biologicals to the spinal cord by microinjection .................................................. 72
Intraventricular injection of drugs .............................................................................................................. 73

Strategies for drug delivery to the CNS across the BBB ............................................................................. 73
Increasing the permeability (opening) of the BBB ....................................................................................... 74
Osmotic opening of the BBB ......................................................................................................................... 74
Focal disruption of BBB by ultrasound ......................................................................................................... 74
Chemical opening of the BBB ...................................................................................................................... 74
Cerebral vasodilatation to open the BBB ...................................................................................................... 75
Modulation of vascular permeability by laser irradiation ........................................................................... 75
Neurostimulation for opening BBB ............................................................................................................. 76
Use of nitric oxide donors to open the BBB ................................................................................................... 76
Manipulation of the sphingosine 1-phosphate receptor system ................................................................... 76
Pharmacological strategies to facilitate transport across the BBB ............................................................... 77
2B-Trans™ technology ................................................................................................................................. 77
ABC afflux transporters and penetration of the BBB ................................................................................... 77
Carrier-mediated drug delivery across the BBB ............................................................................................ 78
Fusion of receptor-binding peptide from apoe with therapeutic protein ..................................................... 79
G-Technology® ............................................................................................................................................ 79
Glycosylation Independent Lysosomal Targeting ....................................................................................... 80
Inhibition of P-glycoprotein to enhance drug delivery across the BBB ...................................................... 80
LipoBridge™ technology ............................................................................................................................ 80
Modification of the drug to enhance its lipid solubility ................................................................................ 81
Monoclonal antibody fusion proteins .......................................................................................................... 81
Neuroimmunophils ....................................................................................................................................... 82
Peptide-mediated transport across the BBB .................................................................................................. 82
Prodrug bioconversion strategies and their CNS selectivity ...................................................................... 84
Transport of small molecules across the BBB .............................................................................................. 84
Transport across the BBB by short chain oligoglycerolipids ................................................................... 85
Transvascular delivery across the BBB ....................................................................................................... 85
Trojan horse approach .................................................................................................................................. 85
Role of the transferrin-receptor system in CNS drug delivery .................................................................. 86
Use of receptor-mediated transcytosis to cross the BBB ....................................................................... 86
Cell-based drug delivery to the CNS ........................................................................................................... 88
Activated T lymphocytes ............................................................................................................................ 88
Microglial cells ............................................................................................................................................ 88
Neural stem cells ......................................................................................................................................... 88
Drug delivery to the CNS by using novel formulations ............................................................................. 89
Crystalline formulations ............................................................................................................................... 89
Liposomes .................................................................................................................................................... 89
Monoclonal antibodies ............................................................................................................................... 90
Microspheres ............................................................................................................................................... 91
Microbeads .................................................................................................................................................. 91
Brain-targeted chemical delivery systems ................................................................................................ 92

Nanotechnology-based drug delivery to CNS .............................................................................................. 92
Nanoparticles for drug delivery across the BBB ......................................................................................... 92
Nanolift™ technology for crossing the BBB ............................................................................................... 93
Masking BBB-limiting characteristics by nanotechnology ...................................................................... 93
Nanovesicles for transport across BBB ...................................................................................................... 94
Peptide-nanoparticle conjugates for crossing the BBB ............................................................................ 94
Penetration of BBB by nanoparticles coated with polysorbate 80 ........................................................... 94
Transcytosis of transferrin-containing nanoparticles across the BBB ...................................................... 95
Nanotechnology-based devices and implants for CNS ............................................................................. 95

Biochip implants for drug delivery to the CNS ........................................................................................... 95
Controlled-release microchip ...................................................................................................................... 95
Retinal implant chip ..................................................................................................................................... 96

Convection-enhanced delivery to the CNS .................................................................................................. 96
Systemic administration of drugs for CNS effects ...................................................................................... 97
Sustained and controlled release drug delivery to the CNS ................................................................... 97
Fast dissolving oral selegiline ..................................................................................................................... 99
Choice of the route of systemic delivery for effect on the CNS disorders .............................................. 99

Methods of delivery of biopharmaceuticals to the CNS ........................................................................... 100
Delivery of biopharmaceuticals across the BBB .......................................................................................... 100
Methods of delivery of peptides for CNS disorders .................................................................................. 100
Alteration of properties of the BBB for delivery of peptides .................................................................. 100
Challenges for delivery of peptides across the BBB ................................................................................. 101
CBS delivery of peptides via conjugation to biological carriers ............................................................ 101
Delivery of conopeptides to the brain .......................................................................................................... 101
Direct delivery of neuropeptides into the brain ........................................................................................... 102
Molecular manipulations of peptides to facilitate transport into CNS .................................................... 102
Transport to spinal cord motor neurons after peripheral injection ......................................................... 103
Transnasal administration of neuropeptides ............................................................................................... 103
4. Delivery of Cell, Gene and Antisense Therapies to the CNS

Introduction .................................................. 114

Cell therapy of neurological disorders ......................... 114

Methods for delivering cell therapies in CNS disorders .......... 114

Cerebrospinal fluid-stem cell interactions for therapy of CNS disorders ........................................ 115

Engineered stem cells for drug delivery to the brain .......... 115

Encapsulated cells ............................................ 116

Intrathecal delivery of stem cells ................................ 116

Intraparenchymal delivery of stem cells to the spinal cord .... 117

Intravascular administration .................................. 117

Gene therapy techniques for the nervous system ........... 118

Introduction .................................................. 118

Methods of gene transfer to the nervous system ............... 120

AAV vector mediated gene therapy for neurogenetic disorders ..................................................................... 120

Ideal vector for gene therapy of neurological disorders .......... 120

Promoters of gene transfer ....................................... 121

Routes of delivery of genes to the nervous system ............ 121

Direct injection into CNS ....................................... 121

Introduction of the genes into cerebral circulation ........... 122

Introduction of genes into cerebrospinal fluid .................. 122

Intravenous administration of vectors ........................... 122

Delivery of gene therapy to the peripheral nervous system ... 123

Cell-mediated gene therapy of neurological disorders ........ 123

Neuronal cells .................................................. 123

Neural stem cells and progenitor cells .......................... 123

Astrocytes ....................................................... 123

Cerebral endothelial cells ...................................... 124

Implantation of genetically modified encapsulated cells into the brain .................................................. 124

Genetically modified bone marrow cells ......................... 124

Nanoparticles as non-viral vectors for CNS gene therapy ...... 125

Applications of gene therapy for neurological disorders .... 125

Companies involved in cell/gene therapy of neurological disorders ....................................................... 126

Antisense therapy of CNS disorders ........................... 127

Delivery of antisense oligonucleotides to the CNS .......... 128

Delivery of oligonucleotides cross the BBB ...................... 129

Cellular delivery systems for oligonucleotides ................. 129

High-flow microinfusion into the brain parenchyma ............ 130

Systemic administration of peptide nucleic acids .............. 130

Introduction of antisense compounds into the CSF Pathways .................................................................... 130

Intrathecal administration of antisense compounds ............ 131

Intracerebroventricular administration of antisense oligonucleotides ....................................................... 131

Nanoparticle-based delivery of antisense therapy to the CNS .................................................................. 132

Methods of delivery of ribozymes ................................ 132

Delivery aspects of RNAi therapy of CNS disorders ....... 133

Delivery of siRNA to the CNS ..................................... 133

Future drug delivery strategies applicable to the CNS .......... 133

5. Drug Delivery for Treatment of Neurological Disorders ............. 136

Introduction .................................................. 136

Targeted drug delivery for neurological disorders .............. 136

Parkinson’s disease .............................................. 136

Drug delivery systems for Parkinson’s disease ................. 138
Methods of delivery of levodopa in PD ................................................................. 139
Duodenal levodopa infusion ................................................................. 139
Sublingual apomorphine ................................................................. 140
Transdermal drug delivery for PD ................................................................. 140
Transdermal dopamine agonists for PD ................................................................. 140
Transdermal administration of other drugs for PD ................................................................. 142
Intracerebral administration of GDNF ................................................................. 142
Cell therapy for PD .................................................................................. 142
Human dopaminergic neurons for PD ................................................................. 143
Graft survival-enhancing drugs ................................................................. 144
Xenografting porcine fetal neurons ................................................................. 144
Encapsulated cells for PD ................................................................. 145
Stem cells for PD .................................................................................. 145
Engineered stem cells for drug delivery to the brain in PD ................................................................. 146
Human retinal pigment epithelium cells for PD ................................................................. 147
Delivery of cells for PD .................................................................................. 147
Gene therapy for Parkinson disease ................................................................. 147
Rationale .................................................................................. 147
Techniques of gene therapy for PD ................................................................. 148
Companies developing gene therapy for PD ................................................................. 152
RNAI therapy of Parkinson’s disease ................................................................. 153

Alzheimer disease .................................................................................. 153
Drug delivery for Alzheimer disease ................................................................. 154
Blood-brain partitioning of an AMPA receptor modulator ................................................................. 155
Clearing amyloid through the BBB ................................................................. 156
Delivery of the passive antibody directly to the brain ................................................................. 156
Delivery of thyrotropin-releasing hormone analogs by molecular packaging ................................................................. 156
Nanoparticle-based drug delivery for Alzheimer’s disease ................................................................. 156
Perispiral etanercept .................................................................................. 157
Slow release implant of an ACHE inhibitor ................................................................. 158
Intranasal insulin in Alzheimer disease ................................................................. 158
Transdermal drug delivery in Alzheimer’s disease ................................................................. 158
Trojan-horse approach to prevent build-up of Aβ aggregates ................................................................. 159
Cell and gene therapy for Alzheimer disease ................................................................. 159
NGF gene therapy .................................................................................. 159
Neprilysin gene therapy .................................................................................. 160
RNAI therapy of Alzheimer’s disease ................................................................. 161

Huntington’s disease .................................................................................. 161
Treatment of HD .................................................................................. 161
Gene therapy of HD .................................................................................. 162
Encapsulated genetically engineered cellular implants ................................................................. 162
Viral vector mediated administration of neurotrophic factors ................................................................. 162
RNAI therapeutics for the treatment of HD ................................................................. 162

Amyotrophic lateral sclerosis .................................................................................. 163
Treatment of ALS .................................................................................. 163
Drug delivery in ALS .................................................................................. 163
Delivery of stem cell therapy for ALS ................................................................. 164
Gene and antisense therapy of ALS ................................................................. 165
Neurotrophic factor gene therapies of ALS ................................................................. 165
Antisense therapy of ALS .................................................................................. 167
RNAI therapy of amyotrophic lateral sclerosis ................................................................. 167

Cerebrovascular disease .................................................................................. 167
Treatment of stroke .................................................................................. 167
Intraarterial administration of tissue plasminogen activator in stroke ................................................................. 168
Drug delivery for prevention of restenosis of carotid arteries ................................................................. 170
In-stent restenosis .................................................................................. 170
Targeted local anti-restenotic drug delivery .................................................................................. 171
Catheter-based drug delivery for restenosis .................................................................................. 171
Stents for prevention of restenosis .................................................................................. 171
Drug-eluting stents .................................................................................. 172
Antisense approach to prevent restenosis .................................................................................. 173
Drug-eluting stents for the treatment of intracranial atherosclerosis ................................................................. 173
Tissues transplants for stroke .................................................................................. 174
Transplant of encapsulated tissue secreting neurotrophic factors ................................................................. 174
Methods for delivery of neurotrophic factors in stroke .................................................................................. 174
Cell therapy for stroke .................................................................................. 174
Stem cell transplant into the brain .................................................................................. 175
Immortalized cell grafts for stroke .................................................................................. 175
Intravenous infusion of marrow stromal cells .................................................................................. 175
Transplantation of glial cells for SCI ................................................................. 208
Fetal neural grafts for SCI ................................................................. 208
Embryonic stem cells for SCI ................................................................. 208
Schwann cell transplants for SCI ................................................................. 209
Olfactory glial cells for SCI ................................................................. 209
Marrow stromal cells for SCI ................................................................. 210
Intravenous injection of stem cells for spinal cord repair .................................................. 210
Combinatorial approach for regeneration in SCI ................................................................. 211
Cell therapy of syringomyelia ................................................................. 211
Gene therapy of spinal cord injury ................................................................. 211

Drugs delivery in CNS infections ................................................................. 211
Drug delivery in neuroAIDS ................................................................. 212
Drug delivery for miscellaneous neurological disorders .................................................. 212
Drug delivery for CNS involvement in Hunter syndrome .................................................. 212
Intrathecal antisense delivery for spinal muscular atrophy .................................................. 213
Genetically modified stem cells for metachromatic leukodystrophy .................................................. 213
Relief of spasticity by intrathecal baclofen ................................................................. 214

Drug delivery for retinal disorders ................................................................. 214
Age-related macular degeneration ................................................................. 214
Squalamine ................................................................. 215
Combretastatin A4P for myopic macular degeneration .................................................. 215
Gene therapy for AMD ................................................................. 215
Anti-VEGF approach to AMD ................................................................. 216
Delivery of pegaptanib for treatment of AMD ................................................................. 216
Stem cell therapy for retinitis pigmentosa ................................................................. 216
Proliferative retinopathies ................................................................. 217

Drug delivery for inner ear disorders ................................................................. 217
Delivery of stem cells for hearing loss ................................................................. 218
Auditory hair cell replacement by gene therapy ................................................................. 218
Future prospects of drug delivery to the inner ear ................................................................. 218

Drug delivery in psychiatric disorders ................................................................. 219
Delivery of antidepressants ................................................................. 219
Transdermal delivery of antidepressants ................................................................. 220
Nasal delivery of antidepressants ................................................................. 222
Delivery methods and formulations of antipsychotics ................................................................. 222
Long-acting injectable antipsychotics ................................................................. 222
Transdermal haloperidol ................................................................. 223
Transdermal risperidone for treatment of schizophrenia ................................................................. 223
Transdermal buprenorphine for treatment of schizophrenia .................................................. 224
Transnasal oxytocin for schizophrenia ................................................................. 224
Transdermal lithium for bipolar disorder ................................................................. 224

6. Drug delivery for brain tumors ................................................................. 226

Introduction ................................................................. 226
Methods for evaluation of anticancer drug penetration into brain tumor .................................................. 226
Innovative methods of drug delivery for glioblastoma multiforme .................................................. 226

Delivery of anticancer drugs across the blood-brain barrier ................................................................. 227
Anticancer agents with increased penetration of BBB ................................................................. 227
BBB disruption ................................................................. 228
Nanoparticle-based targeted delivery of chemotherapy across the BBB ................................................................. 229
Tyrosine kinase inhibitor increases topotecan penetration into CNS .................................................. 230

Bypassing the BBB by alternative methods of drug delivery ................................................................. 231
Intranasal perillyl alcohol ................................................................. 231
Intraarterial chemotherapy ................................................................. 231

Enhancing tumor permeability to chemotherapy ................................................................. 232
PDE1 inhibitors for increasing BTB permeability ................................................................. 232

Local delivery of therapeutic agents into the brain ................................................................. 232
Biodegradable microspheres containing 5-FU ................................................................. 232
Carmustine biodegradable polymer implants ................................................................. 233
Fibrin glue implants containing anticancer drugs ................................................................. 234
Interstitial delivery of dexamethasone for reduction of peritumor edema ................................................................. 234
Magnetically controlled microspheres ................................................................. 234

Convection-enhanced delivery ................................................................. 234
CED for receptor-directed cytotoxin therapy ................................................................. 234
CED of topotecan ................................................................. 234
CED of a modified diphtheria toxin conjugated to transferrin ................................................................. 235
CED of nanoliposomal CPT-11 ................................................................. 235
CED for delivery 131I-chTNT-1/8 MAb ................................................................. 236

Anticancer drug formulations for targeted delivery to brain tumors ................................................................. 236
Intravenous delivery of anticancer agents bearing transferrin ................................................................. 236
Liposomes for drug delivery to brain tumors ................................................................. 236
Mabs targeted to brain tumors ................................................................. 237
Targeted delivery of drug-peptide conjugates to GBM ................................. 237
Multiple targeted drugs for brain tumors .................................................. 238
Nanoparticles for targeted drug delivery in glioblastoma multiforme .............. 238
Targeted antiangiogenic/apoptotic/cytotoxic therapies ................................ 239
Introduction of the chemotherapeutic agent into the CSF pathways .............. 240
Intraventricular chemotherapy for meningial cancer .................................... 240
Intrathecal chemotherapy ........................................................................ 241
Photodynamic therapy for chemosensitization of brain tumors .................... 241
Nanoparticles for photodynamic therapy of brain tumors ............................. 241
Innovative delivery of radiotherapy to brain tumors .................................... 242
GliaSite Radiation Therapy System .......................................................... 242
Boron neutron capture therapy for brain tumors ........................................ 242
Cell therapy for glioblastoma multiforme .................................................. 243
Mesenchymal stem cells to deliver treatment for gliomas ............................. 243
Gene therapy for glioblastoma multiforme ............................................... 243
Antiangiogenic gene therapy .................................................................... 244
Anticancer drug delivery by genetically engineered MSCs .......................... 245
Intravenous gene delivery with nanoparticles into brain tumors .................. 245
Lipid nanoparticles for delivery of dsRNA molecules targeted to EGFR ......... 245
Neural stem cells for drug/gene delivery to brain tumors ............................. 246
Peptides targeted to glial tumor cells ......................................................... 246
RNAi gene therapy of brain cancer ......................................................... 247
Single-chain antibody-targeted adenoviral vectors ..................................... 247
Targeting normal brain cells with an AAV vector encoding interferon-β ......... 247
Treatment of medulloblastoma by suppressing genes in Shh pathway ........... 248
Viruses-mediated oncolytic therapy of brain cancer .................................... 248
HIV-mediated Oncolyis ........................................................................... 248
Autophagy by conditionally replicating adenoviruses .................................. 249
Reovirus-mediated Oncolyis .................................................................... 249
Measles virus-mediated oncolysis ............................................................. 249
Oncolytic virus targeted to brain tumor stem cells ..................................... 250
Oncolysis with vesicular stomatitis virus .................................................. 250
Future prospects of viral-mediated oncolysis ............................................ 250
Vaccination for glioblastoma multiforme .................................................. 251
7. Markets for Drug Delivery in CNS Disorders ........................................ 252
Introduction ......................................................................................... 252
Methods of calculation of CNS drug delivery markets .................................. 252
Markets for CNS drug delivery technologies ............................................. 252
Drug delivery share in selected CNS markets .......................................... 253
CNS share of drug delivery technologies ................................................. 253
Geographical distribution of CNS drug delivery markets ............................ 254
Impact of improved drug delivery on CNS drug markets ............................ 254
Neurodegenerative disorders .................................................................... 254
Alzheimer disease .................................................................................. 255
Parkinson disease .................................................................................. 255
Huntington disease ................................................................................ 255
Amyotrophic lateral sclerosis ................................................................. 255
Epilepsy .................................................................................................. 256
Migraine and other headaches .................................................................. 256
Stroke ...................................................................................................... 256
Central nervous system trauma ............................................................... 257
Multiple sclerosis .................................................................................... 257
Brain tumors ........................................................................................... 257
Limitations of the current drug delivery technologies for CNS .................... 258
Unmet needs in CNS drug delivery technologies ....................................... 258
Future strategies for expanding CNS drug delivery markets ....................... 259
Education of neurologists ......................................................................... 259
Demonstration of the advantages of the newer methods of delivery ............ 260
Rescue of old products by novel drug delivery methods .............................. 260
Facilitation of the approval process of new drugs ...................................... 260
8. Companies ......................................................................................... 262
Introduction ........................................................................................... 262
Profiles of companies ............................................................................... 262
Collaborations ........................................................................................ 347
9. References ......................................................................................... 350
Tables

Table 1-1: Landmarks in the development of drug delivery to the CNS ........................................ 16
Table 2-1: Proteins expressed at the neurovascular unit .............................................................. 29
Table 2-2: Transporters that control penetration of molecules across the BBB ............................... 34
Table 2-3: Enzymes that control the penetration of molecules across the BBB ............................... 37
Table 2-4: Factors that increase the permeability of the BBB ...................................................... 42
Table 2-5: Diseases with associated disturbances of BBB ............................................................. 47
Table 3-1: Various methods of drug delivery to the central nervous system .................................. 58
Table 3-2: Drugs available for intrathecal administration ............................................................... 67
Table 3-3: Investigational drugs administered by intrathecal route ................................................ 68
Table 3-4: Strategies for drug delivery to the CNS across the BBB ............................................. 73
Table 3-5: Specific inhibitors of P-glycoprotein in clinical development ....................................... 80
Table 3-6: Molecules attached to Trojan horses injected intravenously for CNS effect ................... 85
Table 3-7: Examples of controlled and sustained release drug delivery for CNS disorders .......... 98
Table 3-8: Novel methods of delivery of drugs for CNS disorders ............................................... 99
Table 3-9: Indications for the clinical applications of NTFs in neurologic disorders ...................... 104
Table 3-10: Methods for delivery of neurotrophic factors to the CNS .......................................... 104
Table 4-1: Methods for delivering cell therapies in CNS disorders ............................................. 115
Table 4-2: Classification of methods of gene therapy ................................................................. 119
Table 4-3: Methods of gene transfer as applied to neurologic disorders ..................................... 120
Table 4-4: Potential indications for gene therapy of neurologic disorders .................................... 125
Table 4-5: Companies developing cell/gene therapies for CNS disorders ................................... 126
Table 4-6: Methods of antisense delivery as applied to the CNS ................................................ 128
Table 5-1: Strategies for the treatment of Parkinson's disease ...................................................... 136
Table 5-2: Drug delivery systems for Parkinson's disease ............................................................ 138
Table 5-3: Types of cell used for investigative treatment of Parkinson's disease ......................... 142
Table 5-4: Status of cell therapies in development for Parkinson's disease ................................. 143
Table 5-5: Gene therapy techniques applicable to Parkinson disease ........................................ 148
Table 5-6: Companies developing gene therapy for Parkinson's disease .................................... 153
Table 5-7: Classification of pharmacotherapy for Alzheimer disease .......................................... 153
Table 5-8: Novel drug delivery methods for Alzheimer disease therapies .................................... 155
Table 5-9: Classification of neuroprotective agents for amyotrophic lateral sclerosis .................. 163
Table 5-10: Methods of delivery of therapies in development for ALS ........................................ 164
Table 5-11: Classification of treatments for stroke ....................................................................... 168
Table 5-12: Treatments of stroke involving innovative drug delivery methods ............................ 168
Table 5-13: Drug delivery for prevention of carotid artery restenosis after angioplasty ............. 170
Table 5-14: Gene transfer in animal models of carotid artery restenosis ........................................ 177
Table 5-15: Neuroprotective gene transfer strategies in models of cerebral ischemia .................... 178
Table 5-16: Gene Therapy for reducing cerebral infarction in animal stroke models ................... 179
Table 5-17: Pharmacological agents for treatment of cerebral vasospasm .................................. 180
Table 5-18: Gene therapy strategies for vasospasm ...................................................................... 182
Table 5-19: A classification of drug delivery methods used in management of pain .................... 193
Table 5-20: Spinal administration of drugs for pain ................................................................. 198
Table 5-21: Investigational drugs for pain administered by intrathecal route ............................ 199
Table 5-22: Current management of migraine ............................................................................. 204
Table 5-23: Novel drug delivery methods for migraine ............................................................... 204
Table 6-1: Innovative methods of drug delivery for glioblastoma multiforme ......................... 226
Table 6-2: Strategies for gene therapy of malignant brain tumors ............................................. 243
Table 7-1: Share of drug delivery technologies in selected CNS markets: 2015-2025 .................. 253
Table 7-2: CNS market share of drug delivery technologies 2015-2025 ................................. 253
Table 7-3: Value of CNS drug delivery in the major world markets from 2015-2025 .................. 254
Table 7-4: Limitations of the current drug delivery technologies for CNS ............................... 258
Table 8-1: Collaborations of companies in CNS drug delivery ................................................ 347

Figures

Figure 1-1: Interaction of neurotransmitters with receptors ......................................................... 19
Figure 2-1: The neurovascular unit .......................................................................................... 28
Figure 2-2: Various forms of passage of substances across the blood brain barrier ................. 33
Figure 3-1: Routes of drug delivery to the brain ..................................................................... 59
Figure 3-2: Penetration of CSF into spinal cord .................................................................... 66
Figure 3-3: Disposition of opioids after intrathecal administration ........................................ 69
Figure 3-4: Use of receptor-mediated transcytosis to cross the BBB ....................................... 87
Figure 3-5: Nanotechnology-based strategies for delivery of BDNF to the CNS .......................... 111
Figure 5-1: Oral versus transdermal administration of a drug in Parkinson's disease ........... 141
Figure 5-2: Effect of tyrosine hydroxylase gene delivery on dopamine levels ...................... 149
Figure 6-1: A concept of targeted drug delivery to GBM across the BBB ......................... 229
Figure 7-1: Unmet needs in the CNS drug delivery technologies .............................................. 259